Lorenna Buck is a core member of the Private Equity practice at Boston Consulting Group. She has deep experience in private equity due diligence and growth strategy across a variety of industries such as consumer goods, industrial goods, and health care. 

Lorenna has worked with clients on a wide range of strategic topics, including due diligence (sell- and buy-side) and post-merger integrations; growth strategy and M&A strategy; and organizational effectiveness. 

Prior to joining BCG, Lorenna worked in R&D Strategic Intelligence at AstraZeneca Pharmaceuticals. Lorenna also served on the Board of Directors for the Harvard/MIT Coop Bookstore where she focused on real estate, partnership, and consumer insight strategies.

AREAS OF EXPERTISE

EDUCATION

  • PhD, Biological Engineering, Massachusetts Institute of Technology
  • BSE, Electrical and Biomedical Engineering, Duke University

HONORS AND AWARDS

  • Two BCG Northeastern Awards
  • BCG Key to Purpose Award

Publications and Videos

How Private Equity Can Converge on ESG Data - rectangle

How Private Equity Can Converge on ESG Data

Some of the industry’s top general and limited partners are working toward a standard set of metrics for tracking their portfolio companies’ ESG progress.
How-Private-Equity-Can-Catch-Up-on-Diversity-rectangle.jpg

How Private Equity Can Catch Up on Diversity

PE-owned firms are lagging their public counterparts on diversity, equity, and inclusion. This needs to change.
private-equity-chance-stand-up-for-diversity-inclusion-tcm9-250876.jpg

Private Equity’s Chance to Stand Up for Diversity and Inclusion

Championing inclusiveness at the highest levels of portfolio companies is the right moral choice—and it has practical benefits, too.
pipe-eyeem-tcm9-208919.jpg

How an Independent Market Study Improves Private Equity Exits

A market study delivers an independent, objective assessment to potential buyers of the market, the competitive position, and the growth prospects of a divestiture candidate. It also helps private equity firms prep portfolio companies and their senior management for transactions, in many cases revealing possible strategic moves that could make a company more desirable.
nrdd-exteranl-what-drives-operation-performance-in-biopharma-1694x950-tcm9-59591.jpg

What Drives Operational Performance in Biopharma Clinical R&D?

Biopharma companies are more focused than ever on the operational performance of clinical development. Benchmarking has identified eight factors associated with improved clinical-development performance.
Deep Expertise, Broad Experience